Grants
On-going Grants
Gilead Sciences Inc
Matovu (PI)
01/06/22 - 01/05/28
MU-JHU CARE LTD/MU-JHU Research Collaboration, Makerere University-Kalangala, and Africa Medical and Behavioral Sciences Organization (AMBSO), Uganda
GS-US-412-5624/ PURPOSE 1/ A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection
Role: Principal Investigator
Gilead Sciences Inc
Matovu (PI)
02/01/2019 – 01/31/2024
MU-JHU CARE LTD/MU-JHU Research Collaboration - Kampala, Uganda
Bone Mineral Density in a Cohort of African Women on Depo-Provera and Tenofovir Disoproxil Fumarate Switched to Tenofovir Alafenamide Fumarate (TAF) based ART Anti-Retroviral Therapy.
This study provides a timely opportunity to obtain comprehensive safety data on TAF based ART in the context of hormonal and non-hormonal contraceptive use prior to TAF roll out in resource limited settings.
Role: Principal Investigator
Gilead Sciences Inc
Matovu (PI)
01/06/23 - 01/05/25
MU-JHU CARE LTD/MU-JHU Research Collaboration, Kampala, Uganda
GS-US-216-0128/ A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics
(PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed
Pediatric Participants. Version: Protocol Amendment 9 dated 07 September 2022
Role: Principal Investigator
Gilead Sciences Inc
Matovu (PI)
01/06/23 - 01/05/25
MU-JHU CARE LTD/MU-JHU Research Collaboration, Kampala, Uganda
GS-US-380-1474/ GS-US-380-1474 /A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS9883/Emtricitabine/Tenofovir Alafenamide (GS9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Adolescents and Children. Amendment 7 dated 20 Jun 2023
Role: Principal Investigator
NIH/NICHD
Fowler (PI)
04/01/17-31/01/24
MU-JHU CARE LTD/MU-JHU Research Collaboration in Kampala, Uganda and Johns Hopkins University Research Project in Blantyre, Malawi
Determining Bone Loss and Bone Mineral Density Recovery Following Repeat Pregnancy/Lactation among HIV Women on ART
From this study, we will better understand factors affecting potential recovery of BMD; and to compare BMD and bone biomarker outcomes with age and parity matched women who are not HIV infected.
Role: Co – Investigator
NIH/NICHD
Fowler (PI)
04/01/24-31/01/25
MU-JHU CARE LTD/MU-JHU Research Collaboration in Kampala, Uganda and Johns Hopkins University Research Project in Blantyre, Malawi
Bone Health in Older Ugandan Women with and without HIV
From this study, we will determine bone health and body changes among older (peri-menopausal and
post-menopausal) Ugandan women, comparing those who are living with HIV and on ART, to women without HIV of similar age (age group-matched within +/- 5 years) and socioeconomic background).
Role: Principal Investigator
Completed Grants
University of Iowa | Matovu (PI) | 04/01/2022 – 03/31/2023
The Pelvic Floor Disorders (PFD) Study: Validation of PFDI-20, PFIQ-7, and evaluation of pelvic floor
disorders in parous Ugandan women.
The goal of this research was to determine the prevalence of Pelvic Floor Disorders PFD among a cohort of parous women and to translate/validate into Luganda the Pelvic Floor Distress Inventory (PFDI-20) and Pelvic Floor Impact Questionnaire (PFIQ-7) for Ugandan women of reproductive age in Kampala, Uganda. This study also examined risk factors for the development of PFD in this cohort, specifically examining the associations between physical activity and the development of PFD, depression and the presence of PFD.
Role: Principal Investigator
Gilead Sciences | Matovu (PI) | 05/01/2021 – 10/31/2021
Using Recency Assays to estimate incident HIV infections among Adolescent Girls and Young Women in Hoima and Mityana/Mubende Districts, Uganda.
This was a cross sectional survey aimed at determining HIV incidence in adolescent girls and young women (AGYWs) aged 16-25 years in rural Ugandan settings of Hoima and Mityana/Mubende districts. This survey was conducted in preparation for a Gilead Sciences Inc. sponsored HIV prevention trial that will evaluate the safety and efficacy of twice-yearly long-acting subcutaneous Lenacapavir and daily oral Emtricitabine/Tenofovir Alafenamide for pre-exposure prophylaxis in AGYW at risk of HIV infection.
Role: Principal Investigator
Gilead Sciences | Matovu (PI) | 12/15/2019 – 12/14/2021
Maternal Perinatal and Infant Outcomes in HIV/Hepatitis B Co-infected Women on a Variety of Anti Retroviral Therapy Regimens in the PROMISE Study
With a large repository of data comprising of randomized comparator ART arms, this proposal represented a unique opportunity to examine adverse maternal and infant outcomes of HIV/HBV co-infection. We shall be in a position to inform WHO and other country HBV guidelines of the need incorporate mitigation strategies which may have beneficial effects beyond HBV transmission.
Role: Principal Investigator
NIAID/NIH | Matovu (PI) | 06/26/15 – 05/31/2020
Bone Mineral Density in a Cohort of Young Women using Depo-Provera and Tenofovir.
This study directly assessed the combined effect of HIV, DMPA and TDF containing ART on BMD and bone turnover among 18 to 30 year old Ugandan women over a two year follow-up period. The study aimed at evaluating HIV treatment complications and addresses an important gap in HIV management highly relevant to both resource limited and resource rich settings.
Role: Principal Investigator
NIH/NICHD | Heffron (PI) | 04/01/17-03/31/22
IDI Partners PrEP Site, Kampala, Uganda
The major goal of this project was to conduct a study entitled, ‘’Impact of Concurrent Initiation of DMPA Contraception and Tenofovir PrEP on Bone Loss in Young Women’’. The proposed study of PrEP and DMPA provides an opportunity to assess clinical safety outcomes related to bone health and kidney function among young Ugandan women with recommendations for the roll out of PrEP in Uganda and similar settings.
Role: Co – Investigator
NIAID/NIH | Fowler (PI) | 12/10/13-11/30/20
MU-JHU HIV Clinical Trials Unit – Kampala, Uganda
The CTU award follows U01 AI48054 as the main support for the MU-JHU clinical trials unit for the prevention and treatment of HIV infection in women and children. The major goal of this project was to conduct pediatric treatment trials and HIV prevention trials including microbicides at clinical research sites in Kampala Uganda.
Role: Co-Investigator
